TCM Biotech International Corp. (TPEX:4169)

Market Cap	3.08B
Revenue (ttm)	834.32M
Net Income (ttm)	20.00M
Shares Out	59.05M
EPS (ttm)	0.34
PE Ratio	151.41
Forward PE	38.38
Dividend	0.29 (0.55%)
Ex-Dividend Date	n/a

Volume	20,739
Average Volume	84,121
Open	52.20
Previous Close	52.20
Day's Range	51.20 - 53.00
52-Week Range	43.65 - 63.60
Beta	0.03
RSI	44.62
Earnings Date	Apr 18, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods....

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4169

Financial Performance

In 2023, TCM Biotech International's revenue was 969.62 million, an increase of 20.84% compared to the previous year's 802.42 million. Earnings were 18.57 million, an increase of 1.69%.